• Osteoboost Health (Bone Health Technologies)

  Participated · Equity · Mar 2024

  Osteoboost Health Inc. develops a wearable Class II prescription device worn around the hips that delivers low-magnitude vibration therapy to the lumbar spine and hips as a non-drug treatment for low bone density and osteopenia, particularly in postmenopausal women. The treatment approach is based on research originally funded by NASA and, in a double-blind trial at the University of Nebraska Medical Center, users who adhered to at least three 30-minute sessions per week for 12 months saw bone density loss reduced by 85% in the spine and 55% in the hips, per the company. The device received a Breakthrough Device designation in 2024 and was later cleared via the FDA De Novo pathway; the company began shipping in May. Since launch it has been prescribed by more than 2,500 physicians, including clinicians at over 30 academic medical centers. The company was also named to TIME’s 2025 list of Best Inventions. Osteoboost plans to use the new financing to scale manufacturing, expand clinical research, and broaden commercialization.

• Orchestra BioMed

  Participated · Series D · Jul 2022

  Orchestra BioMed focuses on late-stage device-based cardiology programs, notably AVIM therapy for uncontrolled hypertension in pacemaker-indicated patients and Virtue SAB for coronary artery disease. The company advances technologies through partnership-driven, royalty-based collaborations to accelerate patient access while preserving capital efficiency. Orchestra has an ongoing strategic collaboration with Medtronic to develop AVIM therapy and has amended that agreement to include potential integration into leadless pacemaker systems. Recent financing activity from strategic investors is intended to fund late-stage clinical and development milestones for these programs. Financial arrangements announced include equity/private placement components, a secured subordinated promissory note that can convert to a prepaid revenue share, and royalty commitments to a strategic investor. The transactions are structured to provide near-term capital and align future commercial economics with partners and investors. Orchestra BioMed develops partnered medical device therapies and advances them via strategic collaborations with large medtech companies. Its flagship candidates are BackBeat Cardiac Neuromodulation Therapy (CNT) for lowering blood pressure in patients indicated for pacemakers and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for certain artery disease indications. BackBeat CNT produced statistically significant reductions in 24-hour ambulatory and office systolic blood pressure in the MODERATO II pilot, and Orchestra plans a global pivotal trial in collaboration with Medtronic. The company has a strategic collaboration with Medtronic for development and commercialization of BackBeat CNT (with revenue sharing) and a partnership with Terumo for Virtue SAB (including a $30 million upfront payment and potential milestone payments). Orchestra closed a $110 million Series D and, together with a planned business combination with HSAC2 and supporting forward-purchase and backstop commitments, expects pro forma gross proceeds sufficient to fund operations into 2026; it also has conditional access to up to $40 million in term debt. The combined company is planned to list on Nasdaq under the ticker OBIO and will use proceeds to support pivotal trials scheduled to initiate in 2023 and to expand its partnership-enabled product pipeline. Orchestra BioMed is a biomedical innovation company providing high‑impact solutions for large unmet needs in procedure‑based medicine. Its pipeline includes Virtue® Sirolimus‑Eluting Balloon (SEB) for coronary and peripheral interventions and the Moderato® implantable pulse generator that delivers BackBeat Cardiac Neuromodulation Therapy™ (CNT™) for hypertension. The company announced CE mark approval for Moderato in September 2019 and Virtue SEB received FDA Breakthrough Designations for coronary in‑stent restenosis and below‑the‑knee peripheral artery disease. Orchestra BioMed presented late‑breaking TCT 2019 clinical results showing BackBeat CNT drove a statistically significant and clinically meaningful reduction in 24‑hour ambulatory systolic blood pressure versus control. The company pursues strategic partnerships to commercialize products and recently entered a global strategic partnership with Terumo Corporation for development and commercialization of Virtue SEB. Financially, Orchestra BioMed completed a $34 million financing in July 2019 and has added a $20 million credit facility to accelerate pipeline development and support general corporate purposes. The company states its business model aims to optimize capital efficiency and cash flow while advancing product development and commercialization. Orchestra BioMed develops procedure-based medical-device therapies with a focus on high-impact unmet needs; its lead assets are Virtue SEB for artery disease and BackBeat CNT for hypertension. The company has a global strategic partnership with Terumo to develop and commercialize Virtue SEB, which received FDA Breakthrough Device Designation for coronary in‑stent restenosis in April 2019 and is planned for a U.S. registrational IDE trial within the next year. BackBeat CNT recently completed enrollment in a randomized clinical study and is on track to report six‑month data later in the year. In 2019 the company secured $64 million in capital inflows, including a $30 million up‑front payment from the Terumo partnership, and completed a $34 million Series B‑1 financing to accelerate pipeline development. Orchestra intends to use proceeds to expand development of Virtue SEB and BackBeat CNT, pursue additional global clinical studies, and develop additional sustained‑release sirolimus product candidates in other procedure‑based markets. The company also continues to evaluate selective product acquisitions and licensing opportunities and relies on partnerships with established commercial leaders to drive global commercialization. Orchestra BioMed is a biomedical innovation company based in New Hope, PA, focused on evidence-based therapeutic solutions addressing major unmet medical needs, with a primary focus on cardiovascular disease. The company’s core product development expertise spans drug delivery, interventional devices, bioelectronics and neuromodulation. Its lead product candidates are the Virtue® Sirolimus-Eluting Balloon (SEB), a drug-eluting angioplasty balloon that delivers delayed-release bioabsorbable particle-encapsulated sirolimus, and BackBeat® Cardiac Neuromodulation Therapy (CNT), a patented implantable neuromodulation treatment for hypertension. Orchestra closed a $41M equity financing that included conversion of outstanding debt to equity and a financing structure providing for up to an additional $23M in follow-on financing from existing investors. The company intends to use the funds for continued late-stage clinical development of Virtue SEB and BackBeat CNT. Orchestra also holds a wholly owned subsidiary, FreeHold Surgical®, and significant minority interests in Motus GI® Holdings, Inc. (MOTS) and Vivasure Medical Ltd., which are advancing commercial launches of their respective products.

• Diabeloop

  Participated · Series C · Jun 2022

  Diabeloop develops DBLG1, a closed-loop diabetes management system that integrates a continuous glucose sensor, an insulin pump and AI algorithms to automate insulin delivery for people with type 1 and highly unstable type 1 diabetes. The system’s algorithms analyze real-time glucose data and deliver personalized insulin doses based on patient parameters and entered information. DBLG1 completed clinical trials in 2017 and received CE marking in 2018. The solution is in use by more than 10,000 patients and has been deployed in France, Germany, Italy, Spain, Switzerland and the Netherlands. With a new €15 million funding round, the company intends to accelerate revenue growth of its closed-loop system and prepare the launch of DBLG2, an algorithm integrated into a smartphone app for Android and iOS. The company was founded in 2015 by Guillaume Charpentier and Erik Huneker and has appointed François Miceli as President and CEO. Diabeloop builds machine-learning software and CE-marked closed-loop systems (DBLG1 and DBL-hu) that connect continuous glucose monitors and insulin pumps to automate insulin delivery in real time. Its algorithms personalize therapy, reducing patient decision burden and aiming to improve clinical outcomes and quality of life. The company has commercially launched two products in Europe and was rapidly approaching 10,000 equipped patients one year after launch. Diabeloop also offers a CE-marked data-visualization telemedicine platform for clinicians and is adapting its core algorithm to the connected-pen market and developing smart-watch devices. Founded in 2015 and operating from Paris, the company employs over 160 people. The business plans to use new funding to accelerate commercial roll-out, international expansion and continued product development. Diabeloop is a Grenoble-based medical-technology spin-off founded in 2015 that develops the DBLG1, a hybrid closed-loop system for autonomous type 1 diabetes management. DBLG1 connects a continuous glucose monitor, an insulin patch pump and a locked-down handset that hosts a personalized, self-learning decision algorithm. The system uses layered safety mechanisms and machine-learning expert layers; Diabeloop owns related patents, some jointly with research partner CEA, and co-develops with CEA-Leti and CERITD. A randomized 68-person home trial published in The Lancet Digital Health showed significant improvement in glycemic control and reduced hypoglycemic risk; the study ran in 12 hospitals across France. Pediatric (ages 6–12) and highly unstable diabetes trials are ongoing, and the company plans a larger study for an FDA submission while pursuing reimbursement in France, discussions in Germany, and mid-term expansion across Europe. Diabeloop has also stated it will continue R&D to address other diabetes types and to further reduce the daily mental load of the disease.

No current team members are available.